Pelthos to Merge With Castle Creek Biosciences, Raising $57.5M PIPE
PTHS sits 42% above its 52-week low of $14.06 on light trading volume (0.3× avg).
Summary
Pelthos agreed to merge with Castle Creek Biosciences, issuing 5,200,000 shares (Castle Creek holders ~32.5% pre-PIPE) plus up to $300M in milestones and 5,800,000 contingent shares, alongside a $57.5M Series B PIPE that can reach $80M.
Key Events · M&A and Partnerships · PTHS
-
All-Stock Merger With Castle Creek
Pelthos will issue 5,200,000 shares to Castle Creek holders, who are expected to own about 32.5% of Pelthos post-closing before the PIPE, with Pelthos holders at about 67.5%.
-
Up to $300M in Milestone Payments
Castle Creek holders can receive $50M on a D-Fi clinical milestone by June 30, 2029, $50M on first US commercial sale, $50M at $100M net sales, $75M at $250M and $75M at $500M, plus 5,800,000 contingent shares on FDA approval by March 31, 2036 and 80% of PRV proceeds.
-
$57.5M PIPE, Up to $80M
Investors including Ligand, Nomis Bay and Marshman are buying 57,500 Series B preferred shares at $1,000 stated value plus 496,951 warrants for about $57.5M; the Option Buyer and Other Bridge Buyers can add up to $26.6M and $1.5M, capping the total at $80.0M.
-
Stockholder Approval Already Secured
Holders of about 3.0 million shares, roughly 56.2% of voting power, signed the written consent approving the share issuances, so no further Pelthos stockholder vote is required.
Analysis · PTHS · Life Sciences
Pelthos is acquiring Castle Creek Biosciences in an all-stock merger, issuing 5,200,000 shares that leave Castle Creek holders with roughly 32.5% of the combined company before the concurrent financing. The deal is heavily back-loaded: Castle Creek holders get up to $300 million in cash milestones tied to D-Fi (a gene therapy for epidermolysis bullosa) plus 5,800,000 contingent shares if the FDA approves by March 2036 and 80% of any priority review voucher proceeds. To fund the combined company, Pelthos is raising at least $57.5 million through Series B convertible preferred sold at a $1,000 stated value (converting at $19.67) with 496,951 warrants, expandable to $80 million. Existing holders are diluted by both the merger shares and the preferred, and the preferred carries a 4.99%/9.99% blocker and votes alongside common. The stockholder vote is already done via written consent from holders of about 56.2% of voting power, so the remaining gating items are the Form S-4, HSR clearance and closing the PIPE. The Horizon loan was expanded to $40 million outstanding to help repay Castle Creek's debt.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTHS was trading at $20.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $63.3M. The 52-week trading range was $14.06 to $37.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.